Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Norbert Schmitz

Showing results (351-360 of 385) with videos related to

Pageof 39
Sort By:
The Lancet. Oncology|January 30, 2008
Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20+ B-cell lymphomas: a randomised controlled trial (RICOVER-60)Michael Pfreundschuh, Joerg Schubert, Marita Ziepert, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 20, 2017
Clinical Impact of the Cell-of-Origin Classification and the MYC/ BCL2 Dual Expresser Status in Diffuse Large B-Cell Lymphoma Treated Within Prospective Clinical Trials of the German High-Grade Non-Hodgkin's Lymphoma Study GroupAnnette M Staiger, Marita Ziepert, Heike Horn, et al.
Leukemia|September 19, 2019
A novel lymphoma-associated macrophage interaction signature (LAMIS) provides robust risk prognostication in diffuse large B-cell lymphoma clinical trial cohorts of the DSHNHLAnnette M Staiger, Michael Altenbuchinger, Marita Ziepert, et al.
Hemasphere|February 26, 2026
Autologous stem cell transplantation in major T-cell lymphoma entities: An analysis by the EBMT Lymphoma Working PartyEvgenii Shumilov, Maud Ngoya, Philipp Berning, et al.
Leukemia & Lymphoma|August 26, 2017
Advanced patient age at diagnosis of diffuse large B-cell lymphoma is associated with molecular characteristics including ABC-subtype and high expression of MYCUlrike Paul, Julia Richter, Christiane Stuhlmann-Laiesz, et al.
Blood|March 25, 2009
Comparable survival between HIV+ and HIV- non-Hodgkin and Hodgkin lymphoma patients undergoing autologous peripheral blood stem cell transplantationJosé L Díez-Martín, Pascual Balsalobre, Alessandro Re, et al.
The Lancet. Haematology|July 2, 2026
Autologous and allogeneic haematopoietic cell transplantation in adult patients with Hodgkin lymphoma: recommendations from the EBMT Practice Harmonisation and Guidelines Committee and Lymphoma Working PartyAli Bazarbachi, Ranjana Advani, Sairah Ahmed, et al.
BMC Pregnancy and Childbirth|May 7, 2015
QF2011: a protocol to study the effects of the Queensland flood on pregnant women, their pregnancies, and their children's early developmentSuzanne King, Sue Kildea, Marie-Paule Austin, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 25, 2016
Randomized, Double-Blind, Phase III Trial of Enzastaurin Versus Placebo in Patients Achieving Remission After First-Line Therapy for High-Risk Diffuse Large B-Cell LymphomaMichael Crump, Sirpa Leppä, Luis Fayad, et al.
Blood Advances|December 3, 2021
Outcome of allogeneic transplantation for mature T-cell lymphomas: impact of donor source and disease characteristicsMehdi Hamadani, Maud Ngoya, Anna Sureda, et al.
Pageof 39

Showing results (351-360 of 385) with videos related to

Sort By:
Pageof 39
The Lancet. Oncology|January 30, 2008
Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20+ B-cell lymphomas: a randomised controlled trial (RICOVER-60)Michael Pfreundschuh, Joerg Schubert, Marita Ziepert, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 20, 2017
Clinical Impact of the Cell-of-Origin Classification and the MYC/ BCL2 Dual Expresser Status in Diffuse Large B-Cell Lymphoma Treated Within Prospective Clinical Trials of the German High-Grade Non-Hodgkin's Lymphoma Study GroupAnnette M Staiger, Marita Ziepert, Heike Horn, et al.
Leukemia|September 19, 2019
A novel lymphoma-associated macrophage interaction signature (LAMIS) provides robust risk prognostication in diffuse large B-cell lymphoma clinical trial cohorts of the DSHNHLAnnette M Staiger, Michael Altenbuchinger, Marita Ziepert, et al.
Hemasphere|February 26, 2026
Autologous stem cell transplantation in major T-cell lymphoma entities: An analysis by the EBMT Lymphoma Working PartyEvgenii Shumilov, Maud Ngoya, Philipp Berning, et al.
Leukemia & Lymphoma|August 26, 2017
Advanced patient age at diagnosis of diffuse large B-cell lymphoma is associated with molecular characteristics including ABC-subtype and high expression of MYCUlrike Paul, Julia Richter, Christiane Stuhlmann-Laiesz, et al.
Blood|March 25, 2009
Comparable survival between HIV+ and HIV- non-Hodgkin and Hodgkin lymphoma patients undergoing autologous peripheral blood stem cell transplantationJosé L Díez-Martín, Pascual Balsalobre, Alessandro Re, et al.
The Lancet. Haematology|July 2, 2026
Autologous and allogeneic haematopoietic cell transplantation in adult patients with Hodgkin lymphoma: recommendations from the EBMT Practice Harmonisation and Guidelines Committee and Lymphoma Working PartyAli Bazarbachi, Ranjana Advani, Sairah Ahmed, et al.
BMC Pregnancy and Childbirth|May 7, 2015
QF2011: a protocol to study the effects of the Queensland flood on pregnant women, their pregnancies, and their children's early developmentSuzanne King, Sue Kildea, Marie-Paule Austin, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 25, 2016
Randomized, Double-Blind, Phase III Trial of Enzastaurin Versus Placebo in Patients Achieving Remission After First-Line Therapy for High-Risk Diffuse Large B-Cell LymphomaMichael Crump, Sirpa Leppä, Luis Fayad, et al.
Blood Advances|December 3, 2021
Outcome of allogeneic transplantation for mature T-cell lymphomas: impact of donor source and disease characteristicsMehdi Hamadani, Maud Ngoya, Anna Sureda, et al.
Pageof 39